FOXO4-DRI

FOXO4-DRI is a lab made chain of 46 amino acids, the small units that proteins are built from, and a short chain like that is called a peptide. It was built to make worn out cells kill themselves: cells too damaged to divide but not dead are called senescent, and it is meant to clear them. The DRI in the name is two changes made at once. Every building block is swapped for its mirror image form, the way a left hand mirrors a right, and the sequence is then written backwards, so the enzymes that chop peptides up have nothing familiar to grip. Write the sequence backwards and it falls into three pieces: ten letters of HIV-1 Tat, the standard hitchhiker sequence for dragging cargo through a cell membrane, two prolines, and 34 letters matching a human protein called FOXO4 at residues 91 to 124.

FOXO4 is a transcription factor, a protein that switches genes on and off. The idea in the founding paper is that senescent cells survive by parking p53, the tumour suppressor that orders a badly damaged cell to destroy itself, where it cannot act, and that a peptide copying the FOXO4 surface which touches p53 prises the two apart. In a dish that gave a selectivity index of 11.73, meaning it took roughly twelve times as much peptide to halve the viability of ordinary human lung fibroblasts as senescent ones, and that is a ratio of two concentrations rather than a count of cells killed at any one dose. Two things in the record complicate the design. Structural work published in 2025 measured the peptide binding a p53 fragment covering its first 94 residues at 400 plus or minus 280 nanomolar, a soft measurement, which the authors call five times stronger than that fragment's grip on the forkhead domain the peptide copies. And Li and colleagues found that reversing and mirroring a peptide cost 3.2 to 3.3 kilocalories per mole of binding energy on the p53 helix that grips MDM2 and MDMX, two partner proteins of p53, and lost 3.0 and 3.4 in two unrelated proteins, concluding that the strategy works poorly for helical peptides. Different peptide and different target, so not a test of this one.

This entry does not survey what buyers say they are after, so what follows is what the selling rests on. Everything a seller means by anti-ageing, the fur, the activity and the kidney function, comes from Baar and colleagues in Cell in 2017, and the picture that carries it is a mouse with a DNA repair mutation. Independent groups did take up the cell killing and the mechanism, published in Circulation, JCI Insight and Communications Biology, but the later work in aged animals measured narrower things: testosterone, sperm, aortic stiffness. The inventors themselves have moved on. Cleara Biotech, spun out of Erasmus MC on this molecule, calls it the third generation of its anti-senescence drugs and says why it built a fourth, and its leads now are aimed at solid tumours and blood cancers rather than at ageing.

The photograph. The fur and activity results everyone has seen came from XpdTTD/TTD mice, a strain carrying a mutation in Xpd, a gene used both to repair DNA and to read it, which models trichothiodystrophy, a human genetic disease in which sparse brittle fur is present from early life. That mouse is ill rather than old. In the naturally aged mice in the same paper the wording goes soft, that the peptide could improve fur density and responsiveness against robust a few figures earlier, the running wheel was abandoned because the animals varied too much, no survival or lifespan endpoint appears anywhere in that paper, and the longest follow-up was 30 days. A second mistake costs a reader their own check. A PubMed search for the name on the vial returns 19 records and the 2017 paper that everything rests on is not among them, because it never uses the string FOXO4-DRI in its title or abstract, so someone checking the literature in the obvious way can read the entire indexed corpus for the name and still miss the study underneath it.

There is no human safety information, because I found no human. The founding paper's own tolerability sentence is hedged, and what it does report is that platelet levels were not noticeably affected, which is the advantage it claims over ABT-263 and ABT-737, senolytics that cause a dangerous fall in the cells that clot blood. Pointing the other way, Born and colleagues in Circulation in 2023 tested senolytics in pulmonary hypertension: in mice overexpressing the serotonin transporter, given ABT263 or FOXO4-DRI, blood flow through the lungs deteriorated and lung endothelial cells were lost against controls, and they conclude that clearing those cells may worsen pulmonary haemodynamics. The group that measured testosterone flagged a separate worry themselves, that FOXO4 protein sits in testis, placenta and muscle, so special attention must be paid to muscle damage and especially to cardiotoxicity, harm to the heart muscle itself. And I found no carcinogenicity study of a molecule built to grip p53, the most important tumour suppressor in the human genome, nor repeat dose toxicity or immunogenicity work in any species.